SCHEMBL30244992

SCHEMBL30244992

CC(=O)OCCOc1ccc(-c2ccc(C#N)cc2)cc1-c1ccc(N2CCCC2)c(C(C)(C)C)c1

nearest known ligand 0.64

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RARG P13631 11/20 0.64
RARA P10276 10/20 0.64
RARB P10826 10/20 0.64
KDM1A O60341 2/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.36
ALDH1A1 P00352 1/20 0.36
ABCB1 P08183 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
ABCG2 Q9UNQ0 1/20 0.36
MMP2 P08253 1/20 0.35
MMP3 P08254 1/20 0.35
USP14 P54578 1/20 0.35
HRH2 P25021 3/20 0.35
HRH1 P35367 3/20 0.35
HRH3 Q9Y5N1 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25038342 1.00 RARG (0.64) RARGRARARARBKDM1APTGDR2
SCHEMBL25747751 0.89 RARG (0.68) RARGRARARARBALDH1A1MAPT
SCHEMBL30244638 0.89 RARG (0.73) RARGRARARARBPTGDR2HRH2
SCHEMBL25040455 0.89 RARG (0.73) RARGRARARARBPTGDR2HRH2
SCHEMBL25747756 0.88 RARG (0.72) RARGRARARARB
SCHEMBL382029 0.88 RARG (0.83) RARGRARARARB
SCHEMBL25040449 0.87 RARG (0.60) RARGRARARARBPTGDR2HRH2
SCHEMBL25040287 0.87 RARG (0.70) RARGRARARARBALDH1A1GAA
SCHEMBL382222 0.86 RARG (0.66) RARGRARARARBGAAMAPT
SCHEMBL23439863 0.85 RARG (0.66) RARGRARARARBHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230278956-A1 PREPARATION OF TRIFAROTENE AND INTERMEDIATES AND POLYMORPHS THEREOF TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) 2023-09-07 US disclosed
US-11691946-B2 Preparation of Trifarotene and intermediates and polymorphs thereof TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) 2023-07-04 US disclosed
US-20230051259-A1 PREPARATION OF TRIFAROTENE AND INTERMEDIATES AND POLYMORPHS THEREOF TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) 2023-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230051259-A1 PREPARATION OF TRIFAROTENE AND INTERMEDIATES AND POLYMORPHS THEREOF UGT1A4, TBK1, UGT1A7 RARG 761/4885RARA 640/4885RARB 461/4885
US-20230278956-A1 PREPARATION OF TRIFAROTENE AND INTERMEDIATES AND POLYMORPHS THEREOF UGT1A4, TBK1, UGT1A7 RARG 761/4885RARA 640/4885RARB 461/4885
US-11691946-B2 Preparation of Trifarotene and intermediates and polymorphs thereof UGT1A4, TBK1, UGT1A7 RARG 761/4885RARA 640/4885RARB 461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.